What is the recommended pain management protocol following uterine fibroid embolization?

Pain Management After Uterine Fibroid Embolization

For pain management following uterine fibroid embolization (UFE), implement a multimodal opioid-sparing protocol consisting of scheduled NSAIDs (ketorolac or ibuprofen) plus acetaminophen, with opioids reserved for breakthrough pain only, and strongly consider superior hypogastric nerve block (SHNB) during the procedure to facilitate same-day discharge.

Procedural Pain Control Strategy

The most effective approach combines intraprocedural nerve blockade with systemic multimodal analgesia:

During the Procedure

Superior hypogastric nerve block is the single most impactful intervention for post-UFE pain control. The 2024 case-control study 1 demonstrated that SHNB using 20 mL of 0.25% levobupivacaine administered mid-procedure resulted in:

• Significantly lower pain scores during the first 6 hours (median 2.6 vs 3.8, p=0.031)
• 62% same-day discharge success vs 31% without SHNB (p=0.044)
• Reduced opioid requirements (44 mg vs 80 mg oral morphine equivalents, p=0.020)
• Decreased anti-emetic use (45% vs 63%)
• Zero adverse events

Alternative intraprocedural option: Intra-arterial lidocaine (100 mg of 1% lidocaine, 10 mL per uterine artery) administered immediately after embolization reduces pain at 2 hours post-procedure (VAS 42.7 vs 61.1, p<0.02) and decreases morphine consumption (11.2 mg vs 20.2 mg, p<0.03) 2.

Systemic Analgesia Protocol

The 2023 comparative study 3 provides the strongest evidence for an enhanced protocol that achieved 81.4% outpatient success (vs 2.7% with standard protocol):

Pre-procedure:

• Transdermal scopolamine (for anti-emetic effect)
• Lorazepam (for anxiety, if no contraindication to benzodiazepines)

Intra-procedure:

• Minimize procedural fentanyl (lower doses correlate with same-day discharge success)
• Ketorolac IV
• Ondansetron IV
• Acetaminophen IV

Post-procedure (first 24 hours):

• Scheduled NSAIDs (ketorolac or transition to oral ibuprofen/naproxen)
• Scheduled acetaminophen
• Opioids for breakthrough pain only

Evidence Synthesis

The 2019 systematic review 4 of 26 studies (3,353 patients) found no significant difference between various analgesic protocols when comparing:

• Opioids ± NSAIDs ± acetaminophen alone (mean pain score 4.84)
• Addition of nerve blocks (mean pain score 4.7)
• Addition of intrauterine artery drug administration (mean pain score 4.09)

However, this review predates the superior hypogastric nerve block studies, which show clear benefit. The key finding is that appropriate use of opioids ± NSAIDs ± acetaminophen appears sufficient, but the addition of SHNB provides measurable improvement in early pain control and facilitates discharge.

Clinical Algorithm

For all UFE patients:

1. Pre-procedure preparation:

   • Administer transdermal scopolamine
   • Consider lorazepam for anxious patients (unless contraindicated)
   • Start IV acetaminophen and ketorolac

2. During embolization:

   • Perform SHNB with 20 mL of 0.25% levobupivacaine at L5 vertebral body level mid-procedure 1, 5
   • OR administer intra-arterial lidocaine (100 mg per uterine artery) immediately post-embolization if SHNB not feasible 2
   • Minimize procedural fentanyl dosing

3. Post-procedure (0-24 hours):

   • Scheduled NSAIDs every 6-8 hours
   • Scheduled acetaminophen every 6 hours
   • Opioids (oral morphine or equivalent) for breakthrough pain only
   • Continue anti-emetics as needed

4. Discharge criteria:

   • Pain controlled with oral medications
   • No nausea/vomiting
   • Stable vital signs
   • Patient presenting with bleeding or bulk symptoms (rather than pain) have higher same-day discharge success 3

Important Caveats

Patient selection matters: The 2023 study 3 found that patients presenting primarily with pain symptoms were less likely to achieve same-day discharge (OR 0.31, p=0.04) compared to those with bleeding or bulk symptoms. Set expectations accordingly.

Opioid dosing is inversely related to success: For every 1 mcg increase in procedural fentanyl, patients were 1% less likely to achieve outpatient discharge 3. This emphasizes the importance of the multimodal approach.

Novel alternatives exist: For patients with opioid or benzodiazepine contraindications, a 2025 case report 6 demonstrated successful UFE using combined intra-arterial ropivacaine, SHNB with ropivacaine, and IV acetaminophen, with pain scores of only 1-2/10.

Technical expertise required: SHNB requires knowledge of relevant anatomy (superior hypogastric plexus at L5, proximity to aortic bifurcation and IVC confluence) and image guidance 5. If unavailable, the intra-arterial lidocaine approach provides a simpler alternative.